

12th November, 2025

To, Department of Corporate Services BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref.: Scrip Code No. : 540701 (Equity) : 975834 and 976560 (Debt)	To, The Manager, Listing Department, National Stock Exchange of India Ltd. “Exchange Plaza”, C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DCAL (ii) Series – EQ
--	--

SUB: PRESS RELEASE REGARDING COMPANY’S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS HOLDING AG, ANNOUNCED SUCCESSFUL REFINANCING AND ENHANCEMENT OF THEIR SYNDICATED CREDIT FACILITIES TO SUPPORT CONTINUED GROWTH AND INVESTMENT

REF.: DISCLOSURE UNDER REGULATIONS 30 AND 51 OF SEBI (LISTING OBLIGATION AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir,

Pursuant to Regulations 30 and 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, today the Company announces that its wholly-owned subsidiary, CARBOGEN AMCIS Holding AG., has Announced successful Refinancing and Enhancement of their Syndicated Credit Facilities to Support Continued Growth and Investment.

In this regard, please find enclosed herewith Press Release on the captioned subject.

Kindly take this on your record.

Yours faithfully,

For, Dishman Carbogen Amcis Limited

Shrima Dave
Company Secretary

Encl.: As Above

PRESS RELEASE

DISHMAN CARBOGEN AMCIS LIMITED announces that its wholly-owned subsidiary, CARBOGEN AMCIS Holding AG., has Announced Successful Refinancing and Enhancement of their Syndicated Credit Facilities to Support Continued Growth and Investment

Ahmedabad, India (12-11-2025) - The Company's wholly-owned subsidiary, CARBOGEN AMCIS, a global top-tier Contract Development and Manufacturing Organisation (CDMO), today announced the successful refinancing and enhancement of its credit facilities through the banking syndication led by UBS Switzerland AG.

"The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million, with an accordion feature enabling a further CHF 30 million. This marks a significant step in supporting the company's future growth," said Harshil Dalal, Global Chief Financial Officer. He added, "This brings the total credit capacity available to CARBOGEN AMCIS under the syndicate to CHF 162,235,250 and EUR 50,000,000."

"This remarkable refinancing and enhancement comes at the perfect time, as we begin to execute our vision-based strategy that establishes new fundamental pillars to guide the company's journey over the next 10 to 15 years in the CDMO space, setting new standards focused on innovation, efficiency, environment, and safety," said Arpit Vyas, Global Managing Director. "Our vision is to make significant advances in areas such as continuous flow chemistry, drug conjugation, and digital transformation, with a keen focus on artificial intelligence — all of which will enable the company to continue its organic growth. The enhanced credit facility will further support the consistency and success of these initiatives," he added.

The transaction, led by UBS Switzerland AG with the participation of several leading financial institutions in Switzerland, reflects the strength of CARBOGEN AMCIS's long-term relationships with its banking partners and their confidence in the Group's business strategy and future growth trajectory.

"The successful refinancing marks another important step in CARBOGEN AMCIS's growth journey. It demonstrates the confidence our banking partners have in our long-term strategy and strengthens our ability to invest in the technologies and infrastructure that will support our customers' most advanced development programmes. While our initial investment round supported the expansion of our Drug Product operations in France, we are now focused on broadening our technological capabilities across the global organisation, positioning CARBOGEN AMCIS at the forefront of innovation and delivering greater value to the pharmaceutical industry," said Stephan Fritschi, CEO of CARBOGEN AMCIS.

For further information about CARBOGEN AMCIS and its capabilities, please visit (www.carbogen-amcis.com) or contact Lucie Framinet at lucie.framinet@carbogen-amcis.com or call +33 7 84 23 10 69

Dishman Carbogen Amcis Ltd.
Dishman Corporate House
Iscon-Bopal Road, Ambli
Ahmedabad – 380058 Gujarat, India



CARBOGEN AMCIS AG. (www.carbogen-amcis.com) is a leading service provider offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries across all stages of clinical development and product life cycle. Our integrated services and innovative chemistry solutions support timely and safe drug development, allowing customers to better optimize available resources. CARBOGEN AMCIS AG. is a wholly owned subsidiary of Dishman Carbogen Amcis Limited, Ahmedabad, India.

Dishman Carbogen Amcis Limited (www.imdcal.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. Dishman Carbogen Amcis group improves its customers' businesses by providing a range of development and manufacturing solutions at locations in Europe, China and in India.